There are already mature clinical drugs for the treatment targeting IL1B (such as Anakinra and Canakinumab), and extensive research has been conducted in various inflammatory diseases, cardiovascular diseases, and tumor prevention [19,20]. The gene discussed is IL1B; the disease is cardiovascular disorder.